Novel oral IL-23 Receptor Antagonist Shows Promise in Plaque Psoriasis Treatment
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on March 27th, 2024
|
Psoriasis arises from an inflammatory reaction orchestrated by interleukin-23 (IL-23), prompting current treatments to focus on this cytokine. However, many existing therapies targeting IL-23 are biologics necessitating intravenous or subcutaneous administration, posing inconvenience. Hence, a study was conducted to evaluate the effectiveness of JNJ-77242113, a novel IL-23 receptor antagonist that can be taken orally, in treating plaque psoriasis.
The phase 2 clinical trial enrolled 255 patients with moderate-to-severe plaque psoriasis affecting more than 10% of their total body surface area. Baseline assessment using the Psoriasis Area and Severity Index (PASI) revealed an average score of approximately 19.1, with an average disease duration of around 18.2 years. Prior treatments included systemic therapy for 78% of patients and biologics for approximately 16%. The study aimed to compare the efficacy of five dose levels of JNJ-77242113 against placebo. The five doses of JNJ-77242113 evaluated were 25 mg once daily, 25 mg twice daily, 50 mg once daily, 100 mg once daily, and 100 mg twice daily. After 16 weeks of treatment, the highest dose (100 mg twice daily) of JNJ-77242113 demonstrated a notable reduction in PASI score by 75%, significantly outperforming the 9% reduction observed in the placebo group. Lower dose levels also exhibited significantly greater efficacy compared to the placebo group, although not to the extent seen with the highest dose. Regarding adverse effects, there was no notable increase in adverse events with escalating dose levels.
The phase 2 clinical trial enrolled 255 patients with moderate-to-severe plaque psoriasis affecting more than 10% of their total body surface area. Baseline assessment using the Psoriasis Area and Severity Index (PASI) revealed an average score of approximately 19.1, with an average disease duration of around 18.2 years. Prior treatments included systemic therapy for 78% of patients and biologics for approximately 16%. The study aimed to compare the efficacy of five dose levels of JNJ-77242113 against placebo. The five doses of JNJ-77242113 evaluated were 25 mg once daily, 25 mg twice daily, 50 mg once daily, 100 mg once daily, and 100 mg twice daily. After 16 weeks of treatment, the highest dose (100 mg twice daily) of JNJ-77242113 demonstrated a notable reduction in PASI score by 75%, significantly outperforming the 9% reduction observed in the placebo group. Lower dose levels also exhibited significantly greater efficacy compared to the placebo group, although not to the extent seen with the highest dose. Regarding adverse effects, there was no notable increase in adverse events with escalating dose levels.